Navidea Biopharmaceuticals (NAVB) 10-Q 11 Aug 16 2016 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Jul. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Trading Symbol	NAVB
Entity Central Index Key	810,509
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		155,751,316

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 1,155,641	$ 7,166,260
Restricted cash	500,997
Accounts and other receivables	3,503,055	3,703,186
Inventory, net	769,820	652,906
Prepaid expenses and other	927,269	1,054,822
Total current assets	6,856,782	12,577,174
Property and equipment	3,799,763	3,871,035
Less accumulated depreciation and amortization	2,165,380	1,943,427
Property and equipment, net	1,634,383	1,927,608
Patents and trademarks	222,590	233,596
Less accumulated amortization	39,867	47,438
Patents and trademarks, net	182,723	186,158
Other assets	8,261	273,573
Total assets	8,682,149	14,964,513
Current liabilities:
Accounts payable	5,134,635	1,767,523
Accrued liabilities and other	4,923,824	3,038,713
Deferred revenue, current	681,704	1,044,281
Notes payable, current	51,652,209	333,333
Total current liabilities	62,392,372	6,183,850
Deferred revenue	26,061	192,728
Notes payable, net of discounts of $0 and $2,033,506, respectively	9,519,779	60,746,002
Other liabilities	650,931	1,677,633
Total liabilities	72,589,143	68,800,213
Commitments and contingencies
Stockholders’ deficit:
Preferred stock; $.001 par value; 5,000,000 shares authorized; no shares issued or outstanding at June 30, 2016 and December 31, 2015, respectively
Common stock; $.001 par value; 200,000,000 shares authorized; 155,640,734 and 155,649,665 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively	155,641	155,650
Additional paid-in capital	326,382,014	326,085,743
Accumulated deficit	(390,913,850)	(380,546,651)
Total Navidea stockholders' deficit	(64,376,195)	(54,305,258)
Noncontrolling interest	469,201	469,558
Total stockholders’ deficit	(63,906,994)	(53,835,700)
Total liabilities and stockholders’ deficit	$ 8,682,149	$ 14,964,513

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Preferred Stock, Par or Stated Value Per Share (USD per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share (USD per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	155,640,734	155,649,665
Common Stock, Shares Outstanding	155,640,734	155,649,665
Notes Payable Non Current [Member]
Notes payable, discounts	$ 0	$ 2,033,506

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Revenue:
Lymphoseek sales revenue	$ 4,231,719	$ 1,963,548	$ 8,014,399	$ 3,798,970
Lymphoseek license revenue	245,950	250,000	500,000	333,333
Grant and other revenue	916,811	654,360	1,602,636	844,061
Total revenue	5,394,480	2,867,908	10,117,035	4,976,364
Cost of goods sold	560,740	332,730	1,095,669	781,787
Gross profit	4,833,740	2,535,178	9,021,366	4,194,577
Operating expenses:
Research and development	2,525,581	2,297,074	5,185,101	6,278,362
Selling, general and administrative	2,888,141	4,048,799	6,984,801	9,542,967
Total operating expenses	5,413,722	6,345,873	12,169,902	15,821,329
Income (loss) from operations	(579,982)	(3,810,695)	(3,148,536)	(11,626,752)
Other income (expense):
Interest expense, net	(7,528,475)	(1,575,741)	(9,721,998)	(2,542,317)
Equity in loss of R-NAV, LLC	(2,920)	(6,205)	(15,159)	(268,432)
Loss on disposal of investment in R-NAV, LLC	(39,732)		(39,732)
Change in fair value of financial instruments	1,469,928	(1,852,730)	2,595,287	(125,627)
Loss on extinguishment of debt		(2,440,714)		(2,440,714)
Other, net	(126)	(4,834)	(37,418)	21,698
Total other expense, net	(6,101,325)	(5,880,224)	(7,219,020)	(5,355,392)
Net income (loss)	(6,681,307)	(9,690,919)	(10,367,556)	(16,982,144)
Less loss attributable to noncontrolling interest	(116)	(241)	(357)	(341)
Deemed dividend on beneficial conversion feature of MT Preferred Stock				(46,000)
Net loss attributable to common stockholders	$ (6,681,191)	$ (9,690,678)	$ (10,367,199)	$ (17,027,803)
Loss per common share (basic and diluted)	$ (0.04)	$ (0.06)	$ (0.07)	$ (0.11)
Weighted average shares outstanding (basic and diluted)	155,382,368	150,107,148	155,345,231	149,951,603

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficit - 6 months ended Jun. 30, 2016 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-controlling Interest [Member]
Balance at Dec. 31, 2015	$ (53,835,700)	$ 155,650	$ 326,085,743	$ (380,546,651)	$ 469,558
Balance, shares at Dec. 31, 2015		155,649,665
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issued restricted stock	168	$ 168
Issued restricted stock, shares		168,000
Canceled forfeited restricted stock	(28)	$ (206)	178
Canceled forfeited restricted stock, shares		(206,000)
Issued stock in payment of Board retainers	34,820	$ 29	34,791
Issued stock in payment of Board retainers, shares		29,069
Stock compensation expense	261,302		261,302
Net loss	(10,367,556)			(10,367,199)	(357)
Balance at Jun. 30, 2016	$ (63,906,994)	$ 155,641	$ 326,382,014	$ (390,913,850)	$ 469,201
Balance, shares at Jun. 30, 2016		155,640,734

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities:
Net loss	$ (10,367,556)	$ (16,982,144)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	267,368	299,139
(Gain) loss on disposal and abandonment of assets	(13,861)	14,749
Change in inventory reserve		92,751
Amortization of debt discount and issuance costs	77,964	358,924
Debt discount and issuance costs written off	1,955,541
Prepayment premium and debt collection fees related to long term debt	2,923,271
Compounded interest on long term debt	1,176,931	429,074
Stock compensation expense	261,302	1,519,020
Equity in loss of R-NAV, LLC		241,574
Loss on disposal of investment in R-NAV, LLC	39,732
Change in fair value of financial instruments	(2,595,287)	125,627
Loss on extinguishment of debt		2,440,714
Issued stock to 401(k) plan for employer matching contributions	0	117,099
Changes in operating assets and liabilities:
Accounts receivable	181,810	(1,013,046)
Inventory	(116,914)	(355,475)
Prepaid expenses and other assets	119,592	680,566
Accounts payable	3,367,112	(119,838)
Accrued and other liabilities	1,860,726	(377,132)
Deferred revenue	(529,244)	1,666,667
Net cash used in operating activities	(1,356,693)	(10,792,108)
Cash flows from investing activities:
Purchases of equipment	(1,847)	(27,618)
Proceeds from sales of equipment	45,000	20,300
Patent and trademark costs		(9,993)
Payments on disposal of investment in R-NAV, LLC	(110,000)
Proceeds from disposal of investment in R-NAV, LLC	27,623
Net cash used in investing activities	(39,224)	(17,311)
Cash flows from financing activities:
Proceeds from issuance of MT Preferred Stock and warrants		500,000
Payment of preferred stock issuance costs		(12,587)
Proceeds from issuance of common stock	140	60,422
Payment of tax withholdings related to stock-based compensation		(23,468)
Proceeds from notes payable		54,500,000
Payment of debt-related costs	(3,923,271)	(3,902,487)
Principal payments on notes payable	(189,163)	(30,000,000)
Restricted cash held for payment against debt	(500,997)
Payments under capital leases	(1,411)	(1,232)
Net cash (used in) provided by financing activities	(4,614,702)	21,120,648
Net (decrease) increase in cash	(6,010,619)	10,311,229
Cash, beginning of period	7,166,260	5,479,006
Cash, end of period	1,155,641	15,790,235
Directors [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Value of restricted stock issued to directors	$ 34,820	$ 69,623

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies a. Basis of Presentation: The information presented as of June 30, 2016 and for the three-month and six-month periods ended June 30, 2016 and 2015 is unaudited, but includes all adjustments (which consist only of normal recurring adjustments) that the management of Navidea Biopharmaceuticals, Inc. (Navidea, the Company, or we) believes to be necessary for the fair presentation of results for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The balances as of June 30, 2016 and the results for the interim periods are not necessarily indicative of results to be expected for the year. The consolidated financial statements should be read in conjunction with Navidea’s audited consolidated financial statements for the year ended December 31, 2015, which were included as part of our Annual Report on Form 10-K. Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (MT). All significant inter-company accounts were eliminated in consolidation. Prior to termination of Navidea’s joint venture with R-NAV, LLC (R-NAV), Navidea's investment in R-NAV was being accounted for using the equity method of accounting and was therefore not consolidated. See Note 7. b. Financial Instruments and Fair Value: In accordance with current accounting standards, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 3. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: (1) Cash, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: The carrying amounts approximate fair value because of the short maturity of these instruments. At June 30, 2016, restricted cash represents the balance in an account that is under the control of Capital Royalty Partners II L.P. (CRG). See Note 9. At June 30, 2016, approximately $894,000 of accounts payable was being disputed by the Company related to unauthorized expenditures by a former executive. (2) Notes payable: The carrying value of our debt at June 30, 2016 and December 31, 2015 primarily consists of the face amount of the notes less unamortized discounts. See Note 8. At June 30, 2016 and December 31, 2015, certain notes payable were also required to be recorded at fair value. The estimated fair value of our debt was calculated using a discounted cash flow analysis as well as a Monte Carlo simulation. These valuation methods include Level 3 inputs such as the estimated current market interest rate for similar instruments with similar creditworthiness. Unrealized gains and losses on the fair value of the debt are classified in other expenses as a change in the fair value of financial instruments in the consolidated statements of operations. At June 30, 2016, the fair value of our notes payable is approximately $61.2 million, equal to the carrying value of $61.2 million. (3) Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 as of June 30, 2016 and December 31, 2015 were included in other liabilities on the consolidated balance sheets. The assumptions used to calculate fair value as of June 30, 2016 and December 31, 2015 included volatility, a risk-free rate and expected dividends. In addition, we considered non-performance risk and determined that such risk is minimal. Unrealized gains and losses on the derivatives are classified in other expenses as a change in the fair value of financial instruments in the statements of operations. See Note 3. c. Revenue Recognition: We currently generate revenue primarily from sales of Lymphoseek ® We earn additional revenues based on a percentage of the actual net revenues achieved by Cardinal Health on sales to end customers made during each fiscal year. The amount we charge Cardinal Health related to end customer sales of Lymphoseek are subject to a retroactive annual adjustment. To the extent that we can reasonably estimate the end-customer prices received by Cardinal Health, we record sales based upon these estimates at the time of sale. If we are unable to reasonably estimate end customer sales prices related to products sold, we record revenue related to these product sales at the minimum (i.e., floor) price provided for under our distribution agreement with Cardinal Health. During the six-month periods ended June 30, 2016 and 2015, over 99% of Lymphoseek sales were made to Cardinal Health. As of June 30, 2016, approximately 98% of accounts and other receivables were due from Cardinal Health. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may include payment to us of non-refundable upfront license fees, funding or reimbursement of research and development efforts, milestone payments if specified objectives are achieved, and/or royalties on product sales. We evaluate all deliverables within an arrangement to determine whether or not they provide value on a stand-alone basis. We recognize a contingent milestone payment as revenue in its entirety upon our achievement of a substantive milestone if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. We received a non-refundable upfront cash payment of $2.0 million from SpePharm AG upon execution of the SpePharm License Agreement in March 2015. We have determined that the license and other non-contingent deliverables do not have stand-alone value because the license could not be deemed to be fully delivered for its intended purpose unless we perform our other obligations, including specified development work. Accordingly, they do not meet the separation criteria, resulting in these deliverables being considered a single unit of account. As a result, revenue relating to the upfront cash payment was deferred and is being recognized on a straight-line basis over the estimated obligation period of two years. We generate additional revenue from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. Lastly, we recognized revenues from the provision of services to R-NAV and its subsidiaries through the termination of the R-NAV joint venture on May 31, 2016. See Note 7. d. Recent Accounting Pronouncements: In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15, Presentation of Financial Statements-Going Concern . ASU 2014-15 defines when and how companies are required to disclose going concern uncertainties, which must be evaluated each interim and annual period. ASU 2014-15 requires management to determine whether substantial doubt exists regarding the entity's going concern presumption. Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). If substantial doubt exists, certain disclosures are required; the extent of those disclosures depends on an evaluation of management's plans (if any) to mitigate the going concern uncertainty. ASU 2014-15 is effective prospectively for annual periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements, however it may affect our disclosures. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers – Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers – Deferral of the Effective Date In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers – Deferral of the Effective Date In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers – Deferral of the Effective Date In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments–Credit Losses – Measurement of Credit Losses on Financial Instruments e. Reclassifications: Certain reclassifications have been made to the prior year’s financial statements to conform to the 2016 presentation. The reclassifications relate to the presentation of the consolidated statements of cash flows and do not change the consolidated balance sheets, statements of operations, or net cash used in operating activities.

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2016
Liquidity [Abstract]
Liquidity	2. Liquidity All of our material assets, except our intellectual property, have been pledged as collateral for our borrowings under the Term Loan Agreement (the CRG Loan Agreement) with CRG. In addition to the security interest in our assets, the CRG Loan Agreement carries covenants that impose significant requirements on us, including, among others, requirements that we (1) pay all principal, interest and other charges on the outstanding balance of the borrowed funds when due; (2) maintain liquidity of at least $5 million during the term of the CRG Loan Agreement; and (3) meet certain annual EBITDA or revenue targets ($22.5 million of Lymphoseek sales revenue in 2016) as defined in the CRG Loan Agreement. The events of default under the CRG Loan Agreement also include a failure of Platinum-Montaur Life Sciences LLC, an affiliate of Platinum Management (NY) LLC, Platinum Partners Value Arbitrage Fund L.P., Platinum Partners Liquid Opportunity Master Fund L.P., Platinum Liquid Opportunity Management (NY) LLC, and Montsant Partners LLC (collectively, Platinum) to perform its funding obligations under the Platinum Loan Agreement (as defined below) at any time as to which the Company had negative EBITDA for the most recent fiscal quarter, as a result either of Platinum’s repudiation of its obligations under the Platinum Loan Agreement, or the occurrence of an insolvency event with respect to Platinum. Our ability to comply with the covenants of the CRG Loan Agreement may be affected by changes in our business condition or results of our operations, or other events beyond our control. An event of default would entitle CRG to accelerate the maturity of our indebtedness, increase the interest rate from 14% to the default rate of 18% per annum, and invoke other remedies available to it under the loan agreement and the related security agreement. During the second quarter of 2016, CRG alleged multiple claims of default on the CRG Loan Agreement, and filed suit in The District Court of Harris County, Texas. On June 22, 2016, CRG exercised control over one of the Company’s primary bank accounts, withdrawing $4.1 million and applying $3.9 million of the cash to various fees, including collection fees, a prepayment premium and an end-of-term fee. The remaining $189,000 was applied to the principal balance of the debt. As of June 30, 2016, the Company’s unrestricted cash balance was $1.2 million. Also in June 2016, CRG contacted our primary distribution partner, Cardinal Health, and demanded that Cardinal Health make all future payments for Lymphoseek sales directly to CRG, rather than to Navidea. Cardinal Health filed an interpleader in Franklin County, Ohio court, requesting that the court make a determination as to whom Cardinal Health should make such payments. On June 28, 2016, Navidea won a temporary restraining order (TRO) from the Ohio court, allowing the Company to receive 50% of the receivables due from Cardinal Health, with the remaining 50% to be placed in a court-controlled escrow account until the Texas Court has ruled. On August 1, 2016, Navidea successfully negotiated a revised TRO, allowing the Company to receive 75% of the receivables due from Cardinal Health, with the remaining 25% to be placed in escrow until the escrow account reaches $1 million, after which 100% of payments are to be made to Navidea. The Company maintains that CRG’s allegations of multiple events of default under the CRG Loan Agreement are without merit and the Company believes it has defenses against these claims. Furthermore, the Company believes that CRG’s actions constitute a material breach of the CRG Loan Agreement and therefore, the Company is no longer subject to certain provisions of the CRG Loan Agreement. We are continuing to explore alternative financing arrangements in order to refinance the CRG debt. We believe that our best course of action is to refinance the CRG debt and pursue claims for damages. There can be no assurance that CRG will not prevail in exercising control over any additional banking arrangements that the Company creates, that the Company will be able to refinance the CRG debt or that the Company will be successful in its claims for damages. In light of current circumstances, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon its ability to generate sufficient cash flow to sustain its operations on a timely basis, to obtain additional financing as may be required, and to refinance the CRG debt. See Notes 8 and 9. In addition, our Loan Agreement with Platinum (the Platinum Loan Agreement) carries standard non-financial covenants typical for commercial loan agreements, many of which are similar to those contained in the CRG Loan Agreement, that impose significant requirements on us. Our ability to comply with these provisions may be affected by changes in our business condition or results of our operations, or other events beyond our control. The breach of any of these covenants would result in a default under the Platinum Loan Agreement, permitting Platinum to terminate our ability to obtain additional draws under the Platinum Loan Agreement and accelerate the maturity of the debt, subject to the limitations of the Subordination Agreement with CRG. Such actions by Platinum could materially adversely affect our operations, results of operations and financial condition, including causing us to substantially curtail our product development activities. The Platinum Loan Agreement includes a covenant that results in an event of default on the Platinum Loan Agreement upon default on the CRG Loan Agreement. As discussed above, the Company is maintaining its position that CRG’s alleged claims do not constitute events of default under the CRG Loan Agreement and believes it has defenses against such claims. The Company has obtained a waiver from Platinum confirming that we are not in default under the Platinum Loan Agreement as a result of the alleged default on the CRG Loan Agreement and as such, we are currently in compliance with all covenants under the Platinum Loan Agreement. As of June 30, 2016, the outstanding principal balance of the Platinum Note was approximately $9.1 million, with $27.3 million currently available under the credit facility. An additional $15 million is potentially available under the credit facility on terms to be negotiated. However, based on Platinum’s recently stated intent to liquidate their funds, Navidea has substantial doubt about Platinum’s ability to fund future draw requests under the credit facility. The inability to access credit under the Platinum Loan Agreement or other potentially available arrangements could materially adversely affect our operations and financial condition and our ability to continue as a going concern. See Note 8.

Fair Value

Fair Value	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value	3 . Fair Value Platinum has the right to convert all or any portion of the unpaid principal or unpaid interest accrued on all draws under the Platinum credit facility, under certain circumstances. Platinum’s debt instrument, including the embedded option to convert such debt into common stock, is recorded at fair value on the consolidated balance sheets. The estimated fair value of the Platinum notes payable is $9.5 million at June 30, 2016. MT issued warrants to purchase MT Common Stock with certain characteristics including a net settlement provision that require the warrants to be accounted for as a derivative liability at fair value on the consolidated balance sheets. The estimated fair value of the MT warrants is $63,000 at June 30, 2016, and will continue to be measured on a recurring basis. See Note 1(b)(3). The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurring Basis as of June 30, 2016 Description Quoted Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable conversion option $ — $ — $ 416,593 $ 416,593 Liability related to MT warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2015 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable conversion option $ — $ — $ 3,011,880 $ 3,011,880 Liability related to MT warrants — — 63,000 63,000 a. Valuation Processes-Level 3 Measurements: The Company utilizes third-party valuation services that use complex models such as Monte Carlo simulation to estimate the value of our financial liabilities. Each reporting period, the Company provides significant unobservable inputs to the third-party valuation experts based on current internal estimates and forecasts. b. Sensitivity Analysis-Level 3 Measurements: Changes in the Company’s current internal estimates and forecasts are likely to cause material changes in the fair value of certain liabilities. The significant unobservable inputs used in the fair value measurement of the liabilities include the amount and timing of future draws expected to be taken under the Platinum Loan Agreement based on current internal forecasts and management’s estimate of the likelihood of actually making those draws as opposed to obtaining other sources of financing. Significant increases (decreases) in any of the significant unobservable inputs would result in a higher (lower) fair value measurement. A change in one of the inputs would not necessarily result in a directionally similar change in the others. There were no Level 1 liabilities outstanding at any time during the six-month periods ended June 30, 2016 and 2015. There were no transfers in or out of our Level 2 liabilities during the six-month periods ended June 30, 2016 and 2015. Changes in the estimated fair value of our Level 3 liabilities relating to unrealized gains (losses) are recorded as changes in fair value of financial instruments in the consolidated statements of operations. The change in the estimated fair value of our Level 3 liabilities during the three-month periods ended June 30, 2016 and 2015 was a decrease of $1.5 million and an increase of $1.9 million, respectively. The change in the estimated fair value of our Level 3 liabilities during the six-month periods ended June 30, 2016 and 2015 was a decrease of $2.6 million and an increase of $126,000, respectively.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	4. Stock-Based Compensation For the three-month periods ended June 30, 2016 and 2015, our total stock-based compensation expense, which includes reversals of expense for certain forfeited or cancelled awards, was approximately $(79,000) and $412,000, respectively. For the six-month periods ended June 30, 2016 and 2015, our total stock-based compensation expense, which includes reversals of expense for certain forfeited or cancelled awards, was approximately $261,000 and $1.5 million, respectively. We have not recorded any income tax benefit related to stock-based compensation in any of the three-month or six-month periods ended June 30, 2016 and 2015. A summary of the status of our stock options as of June 30, 2016, and changes during the six-month period then ended, is presented below: Six Months Ended June 30, 2016 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at beginning of period 5,437,064 $ 1.96 Granted 459,457 1.05 Exercised — — Canceled and Forfeited (1,504,550 ) 1.58 Expired (299,000 ) 2.42 Outstanding at end of period 4,092,971 $ 1.97 7.0 years $ 21,450 Exercisable at end of period 2,808,491 $ 2.05 6.5 years $ 21,450 A summary of the status of our unvested restricted stock as of June 30, 2016, and changes during the six-month period then ended, is presented below: Six Months Ended June 30, 2016 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 361,000 $ 1.69 Granted 168,000 1.20 Vested (66,000 ) 1.65 Forfeited (206,000 ) 1.77 Unvested at end of period 257,000 $ 1.32 During the six-month period ended June 30, 2016, 66,000 shares of restricted stock held by non-employee directors with an aggregate fair value of $63,360 vested as scheduled according to the terms of the restricted stock agreements. Also during the six-month period ended June 30, 2016, 206,000 shares of unvested restricted stock were forfeited upon resignation of certain directors and an officer. As of June 30, 2016, there was approximately $527,000 of total unrecognized compensation expense related to unvested stock-based awards, which we expect to recognize over the remaining weighted average vesting term of 1.3 years.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is calculated by dividing net income (loss) attributable to common stockholders by the weighted-average number of common shares and, except for periods with a loss from operations, participating securities outstanding during the period. Diluted earnings (loss) per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may be issued by the Company include convertible debt, convertible preferred stock, options and warrants. Diluted earnings (loss) per common share for the six-month periods ended June 30, 2016 and 2015 excludes the effects of 14.7 million and 20.3 million common share equivalents, respectively, since such inclusion would be anti-dilutive. The excluded shares consist of common shares issuable upon exercise of outstanding stock options and warrants, and upon the conversion of convertible debt and convertible preferred stock. The Company’s unvested stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from operations, 257,000 shares of unvested restricted stock for the three-month and six-month periods ended June 30, 2016, and 550,750 shares of unvested restricted stock for the three-month and six-month periods ended June 30, 2015, respectively, were excluded in determining basic and diluted loss per share because such inclusion would be anti-dilutive.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Inventory	6. Inventory All components of inventory are valued at the lower of cost (first-in, first-out) or market. We adjust inventory to market value when the net realizable value is lower than the carrying cost of the inventory. Market value is determined based on estimated sales activity and margins. We estimate a reserve for obsolete inventory based on management’s judgment of probable future commercial use, which is based on an analysis of current inventory levels, estimated future sales and production rates, and estimated shelf lives. The components of inventory as of June 30, 2016 and December 31, 2015 are as follows: June 30, 2016 December 31, 2015 (unaudited) Materials $ — $ 330,000 Work-in-process 65,611 392,457 Finished goods 882,115 275,168 Reserves (177,906 ) (344,719 ) Total $ 769,820 $ 652,906 During the six month-period ended June 30, 2015, we wrote off $120,000 of materials related to production issues. During the six-month periods ended June 30, 2016 and 2015, the Company used $36,000 and $123,000, respectively, of Lymphoseek inventory for clinical study and product development purposes.

Investment in R-NAV, LLC

Investment in R-NAV, LLC	6 Months Ended
	Jun. 30, 2016
Equity Method Investments And Joint Ventures [Abstract]
Investment in R-NAV, LLC	7. Investment in R-NAV, LLC Effective May 31, 2016, Navidea terminated its joint venture with R-NAV. Under the terms of the agreement, Navidea (1) transferred all of its shares of R-NAV, consisting of 1,500,000 Series A Preferred Units and 3,500,000 Common Units, to R-NAV; and (2) paid $110,000 in cash to R-NAV. In exchange, R-NAV (1) transferred all of its shares of TcRA Imaging, Inc. (TcRA) to Navidea, thereby returning the technology licensed to TcRA to Navidea; and (2) forgave the $333,333 remaining on the promissory note. Neither Navidea nor R-NAV has any further obligations of any kind to either party. As a result of this transaction, the Company recognized a loss on disposal of the investment in R-NAV of $39,732 during the second quarter of 2016. Navidea’s investment in R-NAV was being accounted for using the equity method of accounting. Navidea’s equity in the loss of R-NAV was $15,159 and $268,432, respectively, for the six-month periods ended June 30, 2016 and 2015. Navidea’s equity in the loss of R-NAV exceeded our initial investment in R-NAV. As such, the carrying value of the Company’s investment in R-NAV was $0 as of the date of termination. The Company’s obligation to provide $500,000 of in-kind services to R-NAV was being recognized as those services were provided. The Company provided $15,000 and $27,000, respectively, of in-kind services during the six-month periods ended June 30, 2016 and 2015. As of the date of termination, the Company had $383,000 of in-kind services remaining to provide under this obligation. This obligation ceased on May 31, 2016 under the terms of the agreement. Navidea provided additional services to R-NAV in support of its development activities. Such services were immaterial to Navidea’s overall operations.

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2016
Debt Disclosure [Abstract]
Notes Payable	8. Notes Payable Platinum In July 2012, we entered into an agreement with Platinum to provide us with a credit facility of up to $50 million. Following the approval of Lymphoseek, Platinum was committed under the terms of the agreement to extend up to $35 million in debt financing to the Company. During the six-month period ended June 30, 2016, $624,000 of interest was compounded and added to the balance of the Platinum Note. In accordance with the terms of the Section 16(b) Settlement Agreement discussed in Note 15(c), Platinum agreed to forgive interest owed on the credit facility in an amount equal to 6%, effective July 1, 2016. As of June 30, 2016, the outstanding principal balance of the Platinum Note was approximately $9.1 million, with $27.3 million currently available under the credit facility. An additional $15 million is potentially available under the credit facility on terms to be negotiated. However, based on Platinum’s recently stated intent to liquidate their funds, Navidea has substantial doubt about Platinum’s ability to fund future draw requests under the credit facility. The Platinum Note is reflected on the consolidated balance sheets at its estimated fair value, which includes the estimated fair value of the embedded conversion option of $417,000. During the three-month periods ended June 30, 2016 and 2015, changes in the estimated fair value of the Platinum Note were a decrease of $1.5 million and an increase of $1.9 million, respectively, and were recorded as non-cash changes in the fair value of the conversion option. During the six-month periods ended June 30, 2016 and 2015, changes in the estimated fair value of the Platinum Note were a decrease of $2.6 million and an increase of $126,000, respectively, and were recorded as non-cash changes in the fair value of the conversion option. The estimated fair value of the Platinum Note was $9.5 million as of June 30, 2016. The Platinum Loan Agreement includes a covenant that results in an event of default on the Platinum Loan Agreement upon default on the CRG Loan Agreement. As discussed above, the Company is maintaining its position that CRG’s alleged claims do not constitute events of default under the CRG Loan Agreement and believes it has defenses against such claims. The Company has obtained a waiver from Platinum confirming that we are not in default under the Platinum Loan Agreement as a result of the alleged default on the CRG Loan Agreement and as such, we are currently in compliance with all covenants under the Platinum Loan Agreement. Capital Royalty Partners II, L.P. In May 2015, Navidea and its subsidiary Macrophage Therapeutics, Inc., as guarantor, executed a Term Loan Agreement with CRG in its capacity as a lender and as control agent for other affiliated lenders party to the CRG Loan Agreement (collectively, the Lenders) in which the Lenders agreed to make a term loan to the Company in the aggregate principal amount of $50 million (the CRG Term Loan), with an additional $10 million in loans to be made available upon the satisfaction of certain conditions stated in the CRG Loan Agreement. During the six-month period ended June 30, 2016, $553,000 of interest was compounded and added to the balance of the CRG Term Loan. Pursuant to a notice of default letter sent to Navidea by CRG, the Company stopped compounding interest in the second quarter of 2016 and began recording accrued interest. As of June 30, 2016, $2.3 million of accrued interest is included in accrued liabilities and other on the consolidated balance sheets. As of June 30, 2016, the outstanding principal balance of the CRG Term Loan was $51.7 million. In connection with the CRG Loan Agreement, the Company recorded a debt discount related to lender fees and other costs directly attributable to the CRG Loan Agreement totaling $2.2 million, including a $1.0 million facility fee which is payable at the end of the term or when the loan is repaid in full. A long-term liability was recorded for the $1.0 million facility fee. The debt discount was being amortized as non-cash interest expense using the effective interest method over the term of the CRG Loan Agreement. As further described below, the facility fee was fully paid off and the debt discount was accelerated and fully amortized in the second quarter of 2016. The CRG Term Loan is collateralized by a security interest in substantially all of the Company's assets. In addition, the CRG Loan Agreement requires that the Company adhere to certain affirmative and negative covenants, including financial reporting requirements and a prohibition against the incurrence of indebtedness, or creation of additional liens, other than as specifically permitted by the terms of the CRG Loan Agreement. The Lenders may accelerate the payment terms of the CRG Loan Agreement upon the occurrence of certain events of default set forth therein, which include the failure of the Company to make timely payments of amounts due under the CRG Loan Agreement, the failure of the Company to adhere to the covenants set forth in the CRG Loan Agreement, and the insolvency of the Company. The covenants of the CRG Loan Agreement include a covenant that the Company shall have EBITDA of no less than $5 million in each calendar year during the term or revenues from sales of Lymphoseek in each calendar year during the term of at least $22.5 million in 2016, with the target minimum revenue increasing in each year thereafter until reaching $45 million in 2020. However, if the Company were to fail to meet the applicable minimum EBITDA or revenue target in any calendar year, the CRG Loan Agreement provides the Company a cure right if it raises 2.5 times the EBITDA or revenue shortfall in equity or subordinated debt and deposits such funds in a separate blocked account. Additionally, the Company must maintain liquidity, defined as the balance of unencumbered cash and permitted cash equivalent investments, of at least $5 million during the term of the CRG Term Loan. The events of default under the CRG Loan Agreement also include a failure of Platinum to perform its funding obligations under the Platinum Loan Agreement at any time as to which the Company had negative EBITDA for the most recent fiscal quarter, as a result either of Platinum’s repudiation of its obligations under the Platinum Loan Agreement, or the occurrence of an insolvency event with respect to Platinum. On April 7, 2016, we received a notice (the First Notice) from CRG, pursuant to the CRG Loan Agreement. The First Notice claims that Events of Default have occurred under Sections 11.01(m) (alleging that a Change of Control has occurred), 11.01(e) (alleging that the Company’s agreement with Platinum reported in the Company’s Current Report on Form 8-K filed on March 18, 2016 constituted an amendment, modification, waiver or supplement to the Loan Agreement, dated July 25, 2012, between the Company and Platinum that required the written consent of CRG and that a subsidiary of the Company opened a bank account without notifying CRG), and 11.01(d) (alleging that the failure by the Company to notify CRG of a Default itself constitutes an Event of Default) of the Loan Agreement. The Company also learned that CRG filed an Original Petition (the Petition) in the District Court for Harris County, Texas alleging the same Events of Default as set forth in the Notice and seeking an undetermined amount of damages and a declaratory judgment that the Company is in default under the Loan Agreement and that CRG, as a result, is entitled to the remedies set forth in Section 11.02 of the Loan Agreement. In the First Notice, CRG indicated that it elected not to require the amounts due under the CRG Loan Agreement to be immediately due and payable, but claimed that the Obligations under the CRG Loan Agreement shall accrue interest at the default rate of 18% per annum until paid in full. We did not achieve the 2015 annual Lymphoseek sales revenue target of $11 million as initially established under the CRG Loan Agreement, but in December 2015 CRG agreed to a reduction of that target to $10 million (Amendment 1) and we were able to meet that reduced target with Lymphoseek sales revenue of $10.3 million, thereby complying with the covenant. On April 22, 2016 we received an additional notice (the Second Notice) from CRG, pursuant to the CRG Loan Agreement. The Second Notice claims that Amendment 1 is invalid due to the existence of Events of Default at the time of its execution in December 2015 which were not disclosed to CRG at that time. Consequently, CRG claimed that the Company failed to satisfy Section 3(b) of Amendment 1 in order for Amendment 1 to become effective and breached Section 4(a)(iii) of Amendment 1, and as such, Amendment 1 is of no effect and the Company is bound by the 2015 annual Lymphoseek sales revenue target of $11 million as originally set forth in the CRG Loan Agreement. Since the Company’ 2015 Lymphoseek sales revenue was $10.3 million, the Second Notice claims that an additional Event of Default has occurred under Section 11.01(d) of the CRG Loan Agreement. On April 28, 2016, the Company received a further notice (the Third Notice) from CRG informing the Company that CRG commenced exercising its remedies, including with respect to cash collateral. In that regard, CRG informed the Company that it had delivered notices to exercise control of the Company’s accounts pursuant to the blocked account control and pledge collateral account control agreements with CRG. On May 2, 2016, the Company successfully sought a temporary restraining order in Harris County Court, Texas, in which the court enjoined CRG from causing any further “freeze” of the Company’s accounts and required CRG to restore the accounts to the position they were in prior to CRG’s April 28, 2016 acts, pending a more complete review of the Company’s and CRG’s positions in the lawsuit. On May 19, 2016, a hearing was held and on May 24, 2016, the court denied the Company’s request for temporary injunctive relief. On May 31, 2016, CRG declared all of the Company’s obligations under the Loan Agreement and all other loan documents to be immediately due and payable in the amount of $56,157,240.69. The Company disputes the amounts claimed to be due and believes that CRG does not have the right to accelerate the loan. On June 1, 2016, CRG filed a Verified Second Amended Petition and Application for Temporary Injunction in The District Court of Harris County, Texas, seeking to restrain the Company and its subsidiary guarantors from operating or using new accounts established by the Company without having first entered into the requisite blocked account control and pledge collateral account control agreements with CRG. On June 22, 2016, CRG transferred all remaining funds in the Company’s primary bank account pursuant to the blocked account control and pledge collateral account control agreements with CRG to an account or accounts under CRG’s control. CRG subsequently notified the Company that the $4.1 million was used to reimburse CRG for actual costs and expenses incurred by CRG related to the collection of the collateral of $778,000, pay the prepayment premium of $2.1 million and the backend facility fee of $1.0 million, and the remaining $189,000 was applied to the principal balance of the loan. The collection fees and prepayment premium were recorded as interest expense, the backend facility fee reduced the liability that was recorded for that purpose at inception, and the principal payment reduced the balance of the debt during the second quarter of 2016. In addition, the remaining unamortized balance of the debt discount of $2.0 million was recorded as interest expense during the second quarter of 2016. Although we have conservatively categorized these expenses according to the manner in which CRG applied them, we believe the $4.1 million should be applied entirely to the outstanding principal balance of the loan. On July 13, 2016, a hearing was held in The District Court of Harris County, Texas with respect to the aforementioned Application for Temporary Injunction. At the conclusion of the hearing, the Court ordered the parties to mediation and stayed any ruling on CRG’s request for injunctive relief until after a mediation has been completed. On July 20, the parties participated in mediation but were not successful in reaching an agreement. On July 29, 2016, the Harris County, Texas judge recused herself from the case, citing inability to be impartial. A new judge was appointed on July 29, 2016. In June 2016, CRG contacted our primary distribution partner, Cardinal Health, and demanded that Cardinal Health make all future payments for Lymphoseek sales directly to CRG, rather than to Navidea. Cardinal Health filed an interpleader in Franklin County, Ohio court, requesting that the court make a determination as to whom Cardinal Health should make such payments. On June 28, 2016, Navidea won a TRO from the Ohio court, allowing the Company to receive 50% of the receivables due from Cardinal Health, with the remaining 50% to be placed in a court-controlled escrow account until the Texas Court has ruled. On August 1, 2016, Navidea successfully negotiated a revised TRO, allowing the Company to receive 75% of the receivables due from Cardinal Health, with the remaining 25% to be placed in escrow until the escrow account reaches $1 million, after which 100% of payments are to be made to Navidea. The Company maintains that CRG’s allegations of multiple events of default under the CRG Loan Agreement are without merit and the Company believes it has defenses against these claims. Furthermore, the Company believes that CRG’s actions constitute a material breach of the CRG Loan Agreement and therefore, the Company is no longer subject to certain provisions of the CRG Loan Agreement. We are continuing to explore alternative financing arrangements in order to refinance the CRG debt. We believe that our best course of action is to refinance the CRG debt and pursue claims for damages. There can be no assurance that CRG will not prevail in exercising control over any additional banking arrangements that the Company creates, that the Company will be able to refinance the CRG debt or that the Company will be successful in its claims for damages. In light of current circumstances, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon its ability to generate sufficient cash flow to sustain its operations on a timely basis, to obtain additional financing as may be required, and to refinance the CRG debt. See Notes 2 and 9. Based on CRG’s claims that the Company is in default under the terms of the CRG Loan Agreement, and in accordance with current accounting guidance, the Company has classified the balance of the CRG Term Loan as a current liability as of June 30, 2016. R-NAV, LLC Effective May 31, 2016, Navidea terminated its joint venture with R-NAV. In accordance with the terms of the agreement, R-NAV forgave the $333,333 remaining on the promissory note. See Note 7. Summary During the three-month periods ended June 30, 2016 and 2015, we recorded net interest expense of $7.5 million and $1.6 million, respectively, primarily related to our notes payable. Of these amounts, $5,000 and $146,000, respectively, related to amortization of the debt discounts related to our notes payable. An additional $352,000 and $429,000, respectively, of total interest expense was compounded and added to the balance of our notes payable during the three-month periods ended June 30, 2016 and 2015. During the six-month periods ended June 30, 2016 and 2015, we recorded net interest expense of $9.7 million and $2.5 million, respectively, primarily related to our notes payable. Of these amounts, $78,000 and $359,000, respectively, related to amortization of the debt discounts related to our notes payable. An additional $1.2 million and $429,000, respectively, of total interest expense was compounded and added to the balance of our notes payable during the six-month periods ended June 30, 2016 and 2015. The collection fees of $778,000, prepayment premium of $2.1 million, and the remaining unamortized balance of the CRG debt discount of $2.0 million were also recorded as interest expense during the three-month period ended June 30, 2016.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2016
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies Sinotau Litigation On August 31, 2015, Sinotau Pharmaceutical Group (Sinotau) filed a suit for damages, specific performance and injunctive relief against the Company in the United States District Court for the District of Massachusetts alleging breach of a letter of intent for licensing to Sinotau of the Company’s NAV4694 product candidate and technology. The Company believed the suit was without merit and filed a motion to dismiss the action. Since then, the Company has continued discussions with Sinotau in an effort to reach a mutually satisfactory agreement. In July 2016, the Company executed a term sheet with Cerveau Technologies, Inc. (Cerveau) as a designated party for the rights resulting from the relationship between Navidea and Sinotau. The term sheet outlines the terms of a potential agreement between the parties to sublicense NAV4694 to Cerveau in return for license fees, milestone payments and royalties. The term sheet includes a standstill provision that halts the aforementioned litigation unless and until the parties execute a definitive agreement within 60 days. With the exception of certain provisions, the term sheet is non-binding and is subject to the agreement of AstraZeneca, from whom the Company has licensed the NAV4694 technology. At this time, it is not possible to determine whether the parties, including AstraZeneca, will reach a definitive agreement, and thus it is not possible to determine with any degree of certainty the ultimate outcome of this legal proceeding, including making a determination of liability. A dismissal hearing is scheduled for September 2016. CRG Litigation On April 7, 2016, we received a notice (the First Notice) from CRG, pursuant to the CRG Loan Agreement. The First Notice claims that Events of Default have occurred under Sections 11.01(m) (alleging that a Change of Control has occurred), 11.01(e) (alleging that the Company’s agreement with Platinum reported in the Company’s Current Report on Form 8-K filed on March 18, 2016 constituted an amendment, modification, waiver or supplement to the Loan Agreement, dated July 25, 2012, between the Company and Platinum that required the written consent of CRG and that a subsidiary of the Company opened a bank account without notifying CRG), and 11.01(d) (alleging that the failure by the Company to notify CRG of a Default itself constitutes an Event of Default) of the Loan Agreement. The Company also learned that CRG filed an Original Petition (the Petition) in the District Court for Harris County, Texas alleging the same Events of Default as set forth in the Notice and seeking an undetermined amount of damages and a declaratory judgment that the Company is in default under the Loan Agreement and that CRG, as a result, is entitled to the remedies set forth in Section 11.02 of the Loan Agreement. In the First Notice, CRG indicated that it elected not to require the amounts due under the CRG Loan Agreement to be immediately due and payable, but claimed that the Obligations under the CRG Loan Agreement shall accrue interest at the default rate of 18% until paid in full. We did not achieve the 2015 annual Lymphoseek sales revenue target of $11 million as initially established under the CRG Loan Agreement, but in December 2015 CRG agreed to a reduction of that target to $10 million (Amendment 1) and we were able to meet that reduced target with Lymphoseek sales revenue of $10.3 million, thereby complying with the covenant. On April 22, 2016 we received an additional notice (the Second Notice) from CRG, pursuant to the CRG Loan Agreement. The Second Notice claims that Amendment 1 is invalid due to the existence of Events of Default at the time of its execution in December 2015 which were not disclosed to CRG at that time. Consequently, CRG claimed that the Company failed to satisfy Section 3(b) of Amendment 1 in order for Amendment 1 to become effective and breached Section 4(a)(iii) of Amendment 1, and as such, Amendment 1 is of no effect and the Company is bound by the 2015 annual Lymphoseek sales revenue target of $11 million as originally set forth in the CRG Loan Agreement. Since the Company’s 2015 Lymphoseek sales revenue was $10.3 million, the Second Notice claims that an additional Event of Default has occurred under Section 11.01(d) of the CRG Loan Agreement. On April 28, 2016, the Company received a further notice (the Third Notice) from CRG informing the Company that CRG commenced exercising its remedies, including with respect to cash collateral. In that regard, CRG informed the Company that it had delivered notices to exercise control of the Company’s accounts pursuant to the blocked account control and pledge collateral account control agreements with CRG. On May 2, 2016, the Company successfully sought a temporary restraining order in Harris County Court, Texas, in which the court enjoined CRG from causing any further “freeze” of the Company’s accounts and required CRG to restore the accounts to the position they were in prior to CRG’s April 28, 2016 acts, pending a more complete review of the Company’s and CRG’s positions in the lawsuit. On May 19, 2016, a hearing was held and on May 24, 2016, the court denied the Company’s request for temporary injunctive relief. On May 31, 2016, CRG declared all of the Company’s obligations under the Loan Agreement and all other loan documents to be immediately due and payable in the amount of $56,157,240.69. The Company disputes the amounts claimed to be due and believes that CRG does not have the right to accelerate the loan. On June 1, 2016, CRG filed a Verified Second Amended Petition and Application for Temporary Injunction in The District Court of Harris County, Texas, seeking to restrain the Company and its subsidiary guarantors from operating or using new accounts established by the Company without having first entered into the requisite blocked account control and pledge collateral account control agreements with CRG. On June 22, 2016, CRG transferred all remaining funds in the Company’s primary bank account pursuant to the blocked account control and pledge collateral account control agreements with CRG to an account or accounts under CRG’s control. CRG subsequently notified the Company that the $4.1 million was used to reimburse CRG for actual costs and expenses incurred by CRG related to the collection of the collateral of $778,000, pay the prepayment premium of $2.1 million and the backend facility fee of $1.0 million, and the remaining $189,000 was applied to the principal balance of the loan. On July 13, 2016, a hearing was held in The District Court of Harris County, Texas with respect to the aforementioned Application for Temporary Injunction. At the conclusion of the hearing, the Court ordered the parties to mediation and stayed any ruling on CRG’s request for injunctive relief until after a mediation has been completed. On July 20, the parties participated in mediation but were not successful in reaching an agreement. On July 29, 2016, the Harris County, Texas judge recused herself from the case, citing inability to be impartial. A new judge was appointed on July 29, 2016. Also in June 2016, CRG contacted our primary distribution partner, Cardinal Health, and demanded that Cardinal Health make all future payments for Lymphoseek sales directly to CRG, rather than to Navidea. Cardinal Health filed an interpleader in Franklin County, Ohio court, requesting that the court make a determination as to whom Cardinal Health should make such payments. On June 28, 2016, Navidea won a TRO from the Ohio court, allowing the Company to receive 50% of the receivables due from Cardinal Health, with the remaining 50% to be placed in a court-controlled escrow account until the Texas Court has ruled. On August 1, 2016, Navidea successfully negotiated a revised TRO, allowing the Company to receive 75% of the receivables due from Cardinal Health, with the remaining 25% to be placed in escrow until the escrow account reaches $1 million, after which 100% of payments are to be made to Navidea. The Company maintains that CRG’s allegations of multiple events of default under the CRG Loan Agreement are without merit and the Company believes it has defenses against these claims. Furthermore, the Company believes that CRG’s actions constitute a material breach of the CRG Loan Agreement and therefore, the Company is no longer subject to certain provisions of the CRG Loan Agreement. We are continuing to explore alternative financing arrangements in order to refinance the CRG debt. We believe that our best course of action is to refinance the CRG debt and pursue claims for damages. There can be no assurance that CRG will not prevail in exercising control over any additional banking arrangements that the Company creates, that the Company will be able to refinance the CRG debt or that the Company will be successful in its claims for damages. In light of current circumstances, the ability of the Company to continue as a going concern is in substantial doubt and dependent upon its ability to generate sufficient cash flow to sustain its operations on a timely basis, to obtain additional financing as may be required, and to refinance the CRG debt. See Notes 2 and 8. Former CEO Arbitration On May 12, 2016 the Company received a demand for arbitration through the American Arbitration Association, Columbus, Ohio, from Ricardo J. Gonzalez, the Company’s then Chief Executive Officer, claiming that he was terminated without cause and, alternatively, that he resigned in accordance with Section 4G of his Employment Agreement pursuant to a notice received by the Company on May 9, 2016. On May 13, 2016, the Company notified Mr. Gonzalez that his failure to undertake responsibilities assigned to him by the Board of Directors and otherwise work after being ordered to do so on multiple occasions constituted an effective resignation, and the Company accepted that resignation. The Company rejected the resignation of Mr. Gonzalez pursuant to Section 4G of his Employment Agreement. Also, the Company notified Mr. Gonzalez that, alternatively, his failure to return to work after the expiration of the cure period provided in his Employment Agreement constituted cause for his termination under his Employment Agreement. Mr. Gonzalez is seeking severance and other amounts claimed to be owed to him under his employment agreement. The Company intends to vigorously defend its position. In addition, the Company has filed counterclaims against Mr. Gonzalez. We are currently in the process of choosing a three-person arbitration board.

Equity Instruments

Equity Instruments	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
Equity Instruments	10 . Equity Instruments During the six-month period ended June 30, 2016, we issued 29,069 shares of our common stock valued at $34,820 to certain members of our Board of Directors who elected to receive stock in lieu of cash compensation.

Stock Warrants

Stock Warrants	6 Months Ended
	Jun. 30, 2016
Warrants And Rights Note Disclosure [Abstract]
Stock Warrants	11. Stock Warrants At June 30, 2016, there are 11.7 million warrants outstanding to purchase Navidea's common stock. The warrants are exercisable at prices ranging from $0.01 to $3.04 per share with a weighted average exercise price of $0.38 per share. The warrants have remaining outstanding terms ranging from 1 to 19 years. In addition, at June 30, 2016, there are 300 warrants outstanding to purchase MT Common Stock. The warrants are exercisable at $2,000 per share.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
Income Taxes	12. Income Taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Due to the uncertainty surrounding the realization of the deferred tax assets in future tax returns, all of the deferred tax assets have been fully offset by a valuation allowance at June 30, 2016 and December 31, 2015. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of June 30, 2016 or December 31, 2015 and we do not expect any significant changes in the next twelve months. Should we need to accrue interest or penalties on uncertain tax positions, we would recognize the interest as interest expense and the penalties as a selling, general and administrative expense. As of June 30, 2016, tax years 2012-2015 remained subject to examination by federal and state tax authorities.

Segments

Segments	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Segments	13. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. Prior to 2015, our products and development programs were all related to diagnostic substances. Our majority-owned subsidiary, Macrophage Therapeutics, Inc., was formed and received initial funding during the first quarter of 2015, which resulted in a re-evaluation of the Company's segment determination. We now manage our business based on two primary types of drug products: (i) diagnostic substances, including Lymphoseek and other diagnostic applications of our Manocept platform, our R-NAV joint venture (terminated on May 31, 2016), NAV4694 and NAV5001 (license terminated in April 2015), and (ii) therapeutic development programs, including therapeutic applications of our Manocept platform and all development programs undertaken by Macrophage Therapeutics, Inc. The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended June 30, 2016 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 4,218,606 $ — $ — $ 4,218,606 International 13,113 — — 13,113 Lymphoseek license revenue 245,950 — — 245,950 Grant and other revenue 865,359 51,452 — 916,811 Total revenue 5,343,028 51,452 — 5,394,480 Cost of goods sold, excluding depreciation and amortization 546,466 — — 546,466 Research and development expenses, excluding depreciation and amortization 2,414,255 111,326 — 2,525,581 Selling, general and administrative expenses, excluding depreciation and amortization (2) 1,135,558 4,430 1,644,649 2,784,637 Depreciation and amortization (3) 14,274 — 103,504 117,778 Income (loss) from operations (4) 1,232,475 (64,304 ) (1,748,153 ) (579,982 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (6,098,405 ) (6,098,405 ) Equity in the loss of R-NAV, LLC — — (2,920 ) (2,920 ) Net income (loss) 1,232,475 (64,304 ) (7,849,478 ) (6,681,307 ) Total assets, net of depreciation and amortization: United States 4,621,738 36,841 3,701,620 8,360,199 International 321,359 — 591 321,950 Capital expenditures — — 1,847 1,847 Three Months Ended June 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 1,962,898 $ — $ — $ 1,962,898 International 650 — — 650 Lymphoseek license revenue 250,000 — — 250,000 Grant and other revenue 654,360 — — 654,360 Total revenue 2,867,908 — — 2,867,908 Cost of goods sold, excluding depreciation and amortization 304,495 — — 304,495 Research and development expenses, excluding depreciation and amortization 2,115,786 176,738 — 2,292,524 Selling, general and administrative expenses, excluding depreciation and amortization (2) 1,529,042 64,018 2,339,207 3,932,267 Depreciation and amortization (3) 32,785 — 116,532 149,317 Loss from operations (4) (1,114,200 ) (240,756 ) (2,455,739 ) (3,810,695 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (5,874,019 ) (5,874,019 ) Equity in the loss of R-NAV, LLC — — (6,205 ) (6,205 ) Net loss (1,114,200 ) (240,756 ) (8,335,963 ) (9,690,919 ) Total assets, net of depreciation and amortization: United States 4,035,926 — 17,690,779 21,726,705 International 470,033 — 1,851 471,884 Capital expenditures 25,492 — 2,126 27,618 Six Months Ended June 30, 2016 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 7,990,026 $ — $ — $ 7,990,026 International 24,373 — — 24,373 Lymphoseek license revenue 500,000 — — 500,000 Grant and other revenue 1,551,184 51,452 — 1,602,636 Total revenue 10,065,583 51,452 — 10,117,035 Cost of goods sold, excluding depreciation and amortization 1,041,105 — — 1,041,105 Research and development expenses, excluding depreciation and amortization 4,831,975 353,126 — 5,185,101 Selling, general and administrative expenses, excluding depreciation and amortization (2) 2,147,664 3,832 4,620,499 6,771,995 Depreciation and amortization (3) 54,564 — 212,806 267,370 Income (loss) from operations (4) 1,990,275 (305,506 ) (4,833,305 ) (3,148,536 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (7,203,861 ) (7,203,861 ) Equity in the loss of R-NAV, LLC — — (15,159 ) (15,159 ) Net income (loss) 1,990,275 (305,506 ) (12,052,325 ) (10,367,556 ) Total assets, net of depreciation and amortization: United States 4,621,738 36,841 3,701,620 8,360,199 International 321,359 — 591 321,950 Capital expenditures — — 1,847 1,847 Six Months Ended June 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 3,793,920 $ — $ — $ 3,793,920 International 5,050 — — 5,050 Lymphoseek license revenue 333,333 — — 333,333 Grant and other revenue 844,061 — — 844,061 Total revenue 4,976,364 — — 4,976,364 Cost of goods sold, excluding depreciation and amortization 725,046 — — 725,046 Research and development expenses, excluding depreciation and amortization 6,006,510 262,752 — 6,269,262 Selling, general and administrative expenses, excluding depreciation and amortization (2) 3,571,217 78,384 5,660,068 9,309,669 Depreciation and amortization (3) 65,841 — 233,298 299,139 Loss from operations (4) (5,392,250 ) (341,136 ) (5,893,366 ) (11,626,752 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (5,086,960 ) (5,086,960 ) Equity in the loss of R-NAV, LLC — — (268,432 ) (268,432 ) Net loss (5,392,250 ) (341,136 ) (11,248,758 ) (16,982,144 ) Total assets, net of depreciation and amortization: United States 4,035,926 — 17,690,779 21,726,705 International 470,033 — 1,851 471,884 Capital expenditures 25,492 — 2,126 27,618 (1) All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies. (2) General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments. (3) (4) Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments. (5) Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Supplemental Disclosure for Sta

Supplemental Disclosure for Statements of Cash Flows	6 Months Ended
	Jun. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure for Statements of Cash Flows	14. Supplemental Disclosure for Statements of Cash Flows During the six-month periods ended June 30, 2016 and 2015, we paid interest aggregating $4.2 million and $2.0 million, respectively. Interest paid during the six-month period ended June 30, 2016 includes collection fees of $778,000 and a prepayment premium of $2.1 million, both of which were withdrawn by CRG from a bank account under their control. During the six month-period ended June 30, 2015, we recorded $1.0 million of end-of-term fees associated with our notes payable to CRG. During the six month-period ended June 30, 2015, we issued 68,157 shares of our common stock as a matching contribution to our 401(k) Plan which were valued at $117,099.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events a. CRG Litigation: On July 13, 2016, a hearing was held in The District Court of Harris County, Texas with respect to the aforementioned Application for Temporary Injunction. At the conclusion of the hearing, the Court ordered the parties to mediation and stayed any ruling on CRG’s request for injunctive relief until after a mediation has been completed. On July 20, the parties participated in mediation but were not successful in reaching an agreement. On July 20, the parties participated in mediation but were not successful in reaching an agreement. On July 29, 2016, the Harris County, Texas judge recused herself from the case, citing inability to be impartial. A new judge was appointed on July 29, 2016. On June 28, 2016, Navidea won a TRO from the Franklin County, Ohio court, allowing the Company to receive 50% of the receivables due from Cardinal Health, with the remaining 50% to be placed in a court-controlled escrow account until the Texas Court has ruled. On August 1, 2016, Navidea successfully negotiated a revised TRO, allowing the Company to receive 75% of the receivables due from Cardinal Health, with the remaining 25% to be placed in escrow until the escrow account reaches $1 million, after which 100% of payments are to be made to Navidea. b. Platinum Waiver: The Platinum Loan Agreement includes a covenant that results in an event of default on the Platinum Loan Agreement upon default on the CRG Loan Agreement. As discussed above, the Company is maintaining its position that CRG’s alleged claims do not constitute events of default under the CRG Loan Agreement and believes it has defenses against such claims. The Company has obtained a waiver from Platinum confirming that we are not in default under the Platinum Loan Agreement as a result of the alleged default on the CRG Loan Agreement and as such, we are currently in compliance with all covenants under the Platinum Loan Agreement. c. Section 16(b) Settlement: As previously reported, in August 2015, a Navidea shareholder filed an action in the United States District Court for the Southern District of New York against two funds managed by Platinum alleging violations of Section 16(b) of the Securities Exchange Act of 1934, as amended, in connection with purchases and sales of the Company’s common stock by the Platinum funds, and seeking disgorgement of the short-swing profits realized by the funds (the Litigation). The Company was named as a nominal defendant in the Litigation. The Litigation was resolved on the terms set forth in a settlement agreement (the Settlement Agreement). The Settlement Agreement was subject to a pending joint motion for approval. The Court approved the settlement on Friday, July 1, 2016. In accordance with the terms of the Settlement Agreement, Platinum agreed to forgive interest owed on the credit facility in an amount equal to 6%, effective July 1, 2016. In addition, Platinum assumed the obligation to pay the legal costs associated with the Litigation. d. Additional Investments in MT: In December 2015 and May 2016, Platinum contributed a total of $200,000 to Macrophage Therapeutics, Inc. MT was not obligated to provide anything in return, although it was considered likely that the MT Board would ultimately authorize some form of compensation to Platinum. As such, the Company recorded the $200,000 as a current liability as of June 30, 2016 pending determination of the form of compensation. In July 2016, MT’s Board of Directors authorized modification of the original investments of $300,000 by Platinum and $200,000 by Dr. Goldberg to a convertible preferred stock with a 10% paid-in-kind (PIK) coupon retroactive to the time the initial investments were made. The conversion price of the preferred will remain at the $500 million initial market cap but a full ratchet will be added to enable the adjustment of conversion price, warrant number and exercise price based on the valuation of the first institutional investment round. In addition, the MT Board authorized issuance of additional convertible preferred stock with the same terms to Platinum as compensation for the additional $200,000 of investments made in December 2015 and May 2016.

Summary of Significant Accoun22

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	a. Basis of Presentation: The information presented as of June 30, 2016 and for the three-month and six-month periods ended June 30, 2016 and 2015 is unaudited, but includes all adjustments (which consist only of normal recurring adjustments) that the management of Navidea Biopharmaceuticals, Inc. (Navidea, the Company, or we) believes to be necessary for the fair presentation of results for the periods presented. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. The balances as of June 30, 2016 and the results for the interim periods are not necessarily indicative of results to be expected for the year. The consolidated financial statements should be read in conjunction with Navidea’s audited consolidated financial statements for the year ended December 31, 2015, which were included as part of our Annual Report on Form 10-K. Our consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Limited and Cardiosonix Ltd, as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (MT). All significant inter-company accounts were eliminated in consolidation. Prior to termination of Navidea’s joint venture with R-NAV, LLC (R-NAV), Navidea's investment in R-NAV was being accounted for using the equity method of accounting and was therefore not consolidated. See Note 7.
Financial Instruments and Fair Value	b. Financial Instruments and Fair Value: In accordance with current accounting standards, the fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1 – Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2 – Quoted prices in markets that are not active or financial instruments for which all significant inputs are observable, either directly or indirectly; and Level 3 – Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. In determining the appropriate levels, we perform a detailed analysis of the assets and liabilities whose fair value is measured on a recurring basis. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3. See Note 3. The following methods and assumptions were used to estimate the fair value of each class of financial instruments: (1) Cash, restricted cash, accounts and other receivables, accounts payable, and accrued liabilities: The carrying amounts approximate fair value because of the short maturity of these instruments. At June 30, 2016, restricted cash represents the balance in an account that is under the control of Capital Royalty Partners II L.P. (CRG). See Note 9. At June 30, 2016, approximately $894,000 of accounts payable was being disputed by the Company related to unauthorized expenditures by a former executive. (2) Notes payable: The carrying value of our debt at June 30, 2016 and December 31, 2015 primarily consists of the face amount of the notes less unamortized discounts. See Note 8. At June 30, 2016 and December 31, 2015, certain notes payable were also required to be recorded at fair value. The estimated fair value of our debt was calculated using a discounted cash flow analysis as well as a Monte Carlo simulation. These valuation methods include Level 3 inputs such as the estimated current market interest rate for similar instruments with similar creditworthiness. Unrealized gains and losses on the fair value of the debt are classified in other expenses as a change in the fair value of financial instruments in the consolidated statements of operations. At June 30, 2016, the fair value of our notes payable is approximately $61.2 million, equal to the carrying value of $61.2 million. (3) Derivative liabilities: Derivative liabilities are related to certain outstanding warrants which are recorded at fair value. Derivative liabilities totaling $63,000 as of June 30, 2016 and December 31, 2015 were included in other liabilities on the consolidated balance sheets. The assumptions used to calculate fair value as of June 30, 2016 and December 31, 2015 included volatility, a risk-free rate and expected dividends. In addition, we considered non-performance risk and determined that such risk is minimal. Unrealized gains and losses on the derivatives are classified in other expenses as a change in the fair value of financial instruments in the statements of operations. See Note 3.
Revenue Recognition	c. Revenue Recognition: We currently generate revenue primarily from sales of Lymphoseek ® We earn additional revenues based on a percentage of the actual net revenues achieved by Cardinal Health on sales to end customers made during each fiscal year. The amount we charge Cardinal Health related to end customer sales of Lymphoseek are subject to a retroactive annual adjustment. To the extent that we can reasonably estimate the end-customer prices received by Cardinal Health, we record sales based upon these estimates at the time of sale. If we are unable to reasonably estimate end customer sales prices related to products sold, we record revenue related to these product sales at the minimum (i.e., floor) price provided for under our distribution agreement with Cardinal Health. During the six-month periods ended June 30, 2016 and 2015, over 99% of Lymphoseek sales were made to Cardinal Health. As of June 30, 2016, approximately 98% of accounts and other receivables were due from Cardinal Health. We also earn revenues related to our licensing and distribution agreements. The terms of these agreements may include payment to us of non-refundable upfront license fees, funding or reimbursement of research and development efforts, milestone payments if specified objectives are achieved, and/or royalties on product sales. We evaluate all deliverables within an arrangement to determine whether or not they provide value on a stand-alone basis. We recognize a contingent milestone payment as revenue in its entirety upon our achievement of a substantive milestone if the consideration earned from the achievement of the milestone (i) is consistent with performance required to achieve the milestone or the increase in value to the delivered item, (ii) relates solely to past performance and (iii) is reasonable relative to all of the other deliverables and payments within the arrangement. We received a non-refundable upfront cash payment of $2.0 million from SpePharm AG upon execution of the SpePharm License Agreement in March 2015. We have determined that the license and other non-contingent deliverables do not have stand-alone value because the license could not be deemed to be fully delivered for its intended purpose unless we perform our other obligations, including specified development work. Accordingly, they do not meet the separation criteria, resulting in these deliverables being considered a single unit of account. As a result, revenue relating to the upfront cash payment was deferred and is being recognized on a straight-line basis over the estimated obligation period of two years. We generate additional revenue from grants to support various product development initiatives. We generally recognize grant revenue when expenses reimbursable under the grants have been paid and payments under the grants become contractually due. Lastly, we recognized revenues from the provision of services to R-NAV and its subsidiaries through the termination of the R-NAV joint venture on May 31, 2016. See Note 7.
Recent Accounting Pronouncements	d. Recent Accounting Pronouncements: In August 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-15, Presentation of Financial Statements-Going Concern . ASU 2014-15 defines when and how companies are required to disclose going concern uncertainties, which must be evaluated each interim and annual period. ASU 2014-15 requires management to determine whether substantial doubt exists regarding the entity's going concern presumption. Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). If substantial doubt exists, certain disclosures are required; the extent of those disclosures depends on an evaluation of management's plans (if any) to mitigate the going concern uncertainty. ASU 2014-15 is effective prospectively for annual periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements, however it may affect our disclosures. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers – Principal versus Agent Considerations (Reporting Revenue Gross versus Net) Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers – Deferral of the Effective Date In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers – Identifying Performance Obligations and Licensing Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers – Deferral of the Effective Date In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers – Narrow-Scope Improvements and Practical Expedients Revenue from Contracts with Customers (Topic 606) Revenue from Contracts with Customers – Deferral of the Effective Date In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments–Credit Losses – Measurement of Credit Losses on Financial Instruments
Reclassifications	e. Reclassifications: Certain reclassifications have been made to the prior year’s financial statements to conform to the 2016 presentation. The reclassifications relate to the presentation of the consolidated statements of cash flows and do not change the consolidated balance sheets, statements of operations, or net cash used in operating activities.

Fair Value (Tables)

Fair Value (Tables)	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value of Liabilities Measured on Recurring Basis	The following tables set forth, by level, financial liabilities measured at fair value on a recurring basis: Liabilities Measured at Fair Value on a Recurring Basis as of June 30, 2016 Description Quoted Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable conversion option $ — $ — $ 416,593 $ 416,593 Liability related to MT warrants — — 63,000 63,000 Liabilities Measured at Fair Value on a Recurring Basis as of December 31, 2015 Description Quoted Prices in Active Markets for Identical Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Platinum notes payable conversion option $ — $ — $ 3,011,880 $ 3,011,880 Liability related to MT warrants — — 63,000 63,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Options Activity	A summary of the status of our stock options as of June 30, 2016, and changes during the six-month period then ended, is presented below: Six Months Ended June 30, 2016 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at beginning of period 5,437,064 $ 1.96 Granted 459,457 1.05 Exercised — — Canceled and Forfeited (1,504,550 ) 1.58 Expired (299,000 ) 2.42 Outstanding at end of period 4,092,971 $ 1.97 7.0 years $ 21,450 Exercisable at end of period 2,808,491 $ 2.05 6.5 years $ 21,450
Schedule of Nonvested Restricted Stock Activity	A summary of the status of our unvested restricted stock as of June 30, 2016, and changes during the six-month period then ended, is presented below: Six Months Ended June 30, 2016 Number of Shares Weighted Average Grant-Date Fair Value Unvested at beginning of period 361,000 $ 1.69 Granted 168,000 1.20 Vested (66,000 ) 1.65 Forfeited (206,000 ) 1.77 Unvested at end of period 257,000 $ 1.32

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
Components of Inventory	The components of inventory as of June 30, 2016 and December 31, 2015 are as follows: June 30, 2016 December 31, 2015 (unaudited) Materials $ — $ 330,000 Work-in-process 65,611 392,457 Finished goods 882,115 275,168 Reserves (177,906 ) (344,719 ) Total $ 769,820 $ 652,906

Segments (Tables)

Segments (Tables)	6 Months Ended
	Jun. 30, 2016
Segment Reporting [Abstract]
Schedule of segment reporting information	The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended June 30, 2016 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 4,218,606 $ — $ — $ 4,218,606 International 13,113 — — 13,113 Lymphoseek license revenue 245,950 — — 245,950 Grant and other revenue 865,359 51,452 — 916,811 Total revenue 5,343,028 51,452 — 5,394,480 Cost of goods sold, excluding depreciation and amortization 546,466 — — 546,466 Research and development expenses, excluding depreciation and amortization 2,414,255 111,326 — 2,525,581 Selling, general and administrative expenses, excluding depreciation and amortization (2) 1,135,558 4,430 1,644,649 2,784,637 Depreciation and amortization (3) 14,274 — 103,504 117,778 Income (loss) from operations (4) 1,232,475 (64,304 ) (1,748,153 ) (579,982 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (6,098,405 ) (6,098,405 ) Equity in the loss of R-NAV, LLC — — (2,920 ) (2,920 ) Net income (loss) 1,232,475 (64,304 ) (7,849,478 ) (6,681,307 ) Total assets, net of depreciation and amortization: United States 4,621,738 36,841 3,701,620 8,360,199 International 321,359 — 591 321,950 Capital expenditures — — 1,847 1,847 Three Months Ended June 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 1,962,898 $ — $ — $ 1,962,898 International 650 — — 650 Lymphoseek license revenue 250,000 — — 250,000 Grant and other revenue 654,360 — — 654,360 Total revenue 2,867,908 — — 2,867,908 Cost of goods sold, excluding depreciation and amortization 304,495 — — 304,495 Research and development expenses, excluding depreciation and amortization 2,115,786 176,738 — 2,292,524 Selling, general and administrative expenses, excluding depreciation and amortization (2) 1,529,042 64,018 2,339,207 3,932,267 Depreciation and amortization (3) 32,785 — 116,532 149,317 Loss from operations (4) (1,114,200 ) (240,756 ) (2,455,739 ) (3,810,695 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (5,874,019 ) (5,874,019 ) Equity in the loss of R-NAV, LLC — — (6,205 ) (6,205 ) Net loss (1,114,200 ) (240,756 ) (8,335,963 ) (9,690,919 ) Total assets, net of depreciation and amortization: United States 4,035,926 — 17,690,779 21,726,705 International 470,033 — 1,851 471,884 Capital expenditures 25,492 — 2,126 27,618 Six Months Ended June 30, 2016 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 7,990,026 $ — $ — $ 7,990,026 International 24,373 — — 24,373 Lymphoseek license revenue 500,000 — — 500,000 Grant and other revenue 1,551,184 51,452 — 1,602,636 Total revenue 10,065,583 51,452 — 10,117,035 Cost of goods sold, excluding depreciation and amortization 1,041,105 — — 1,041,105 Research and development expenses, excluding depreciation and amortization 4,831,975 353,126 — 5,185,101 Selling, general and administrative expenses, excluding depreciation and amortization (2) 2,147,664 3,832 4,620,499 6,771,995 Depreciation and amortization (3) 54,564 — 212,806 267,370 Income (loss) from operations (4) 1,990,275 (305,506 ) (4,833,305 ) (3,148,536 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (7,203,861 ) (7,203,861 ) Equity in the loss of R-NAV, LLC — — (15,159 ) (15,159 ) Net income (loss) 1,990,275 (305,506 ) (12,052,325 ) (10,367,556 ) Total assets, net of depreciation and amortization: United States 4,621,738 36,841 3,701,620 8,360,199 International 321,359 — 591 321,950 Capital expenditures — — 1,847 1,847 Six Months Ended June 30, 2015 Diagnostics Therapeutics Corporate Total Lymphoseek sales revenue: United States (1) $ 3,793,920 $ — $ — $ 3,793,920 International 5,050 — — 5,050 Lymphoseek license revenue 333,333 — — 333,333 Grant and other revenue 844,061 — — 844,061 Total revenue 4,976,364 — — 4,976,364 Cost of goods sold, excluding depreciation and amortization 725,046 — — 725,046 Research and development expenses, excluding depreciation and amortization 6,006,510 262,752 — 6,269,262 Selling, general and administrative expenses, excluding depreciation and amortization (2) 3,571,217 78,384 5,660,068 9,309,669 Depreciation and amortization (3) 65,841 — 233,298 299,139 Loss from operations (4) (5,392,250 ) (341,136 ) (5,893,366 ) (11,626,752 ) Other income (expense), excluding equity in the loss of R-NAV, LLC (5) — — (5,086,960 ) (5,086,960 ) Equity in the loss of R-NAV, LLC — — (268,432 ) (268,432 ) Net loss (5,392,250 ) (341,136 ) (11,248,758 ) (16,982,144 ) Total assets, net of depreciation and amortization: United States 4,035,926 — 17,690,779 21,726,705 International 470,033 — 1,851 471,884 Capital expenditures 25,492 — 2,126 27,618 (1) All sales to Cardinal Health are made in the United States; Cardinal distributes the product throughout the U.S. through its network of nuclear pharmacies. (2) General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments. Marketing and selling expenses are allocated to our individual reportable segments. (3) (4) Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments. (5) Amounts consist primarily of interest income, interest expense, changes in fair value of financial instruments, and losses on debt extinguishment, which are not currently allocated to our individual reportable segments.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Narrative) (Details) - USD ($)	Jun. 30, 2016	Mar. 31, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Accounting Policies [Line Items]
Accounts payable	$ 5,134,635		$ 5,134,635		$ 1,767,523
Fair value of notes payable	61,200,000		61,200,000
Notes payable	61,200,000		61,200,000
Derivative liabilities	$ 63,000		$ 63,000		$ 63,000
Non-refundable upfront cash payment received		$ 2,000,000
Deferred revenue recognition period			2 years
Cardinal Health [Member] | Customer Concentration Risk [Member] | Accounts and Other Receivable [Member]
Accounting Policies [Line Items]
Concentration risk, percentage	98.00%
Cardinal Health [Member] | Customer Concentration Risk [Member] | Minimum [Member] | Lymphoseek sales [Member]
Accounting Policies [Line Items]
Concentration risk, percentage			99.00%	99.00%
Former Executive [Member]
Accounting Policies [Line Items]
Accounts payable	$ 894,000		$ 894,000

Liquidity (Narrative) (Details)

Liquidity (Narrative) (Details) - USD ($)	Jun. 22, 2016	Jun. 30, 2016	Dec. 31, 2015	Aug. 01, 2016	Jun. 28, 2016	Apr. 07, 2016	Jun. 30, 2015	May 15, 2015	Dec. 31, 2014
Liquidity [Line Items]
Cash		$ 1,155,641	$ 7,166,260				$ 15,790,235		$ 5,479,006
Notes payable		61,200,000
Cardinal Health [Member]
Liquidity [Line Items]
Percentage of receivables due from customers					50.00%
Remaining percentage of receivables due from customers held in escrow account					50.00%
Subsequent Event [Member] | Cardinal Health [Member]
Liquidity [Line Items]
Percentage of receivables due from customers				75.00%
Remaining percentage of receivables due from customers held in escrow account				25.00%
Percentage of receivables due from customers after reaching escrow account limit				100.00%
Subsequent Event [Member] | Cardinal Health [Member] | Maximum [Member]
Liquidity [Line Items]
Escrow account threshold target amount				$ 1,000,000
Capital Royalty Partners II LP [Member]
Liquidity [Line Items]
Liquidity minimum		5,000,000						$ 5,000,000
Minimum sales revenue target		$ 22,500,000	$ 11,000,000
Debt instrument default interest rate percentage		18.00%				18.00%
Debt instrument, interest rate		14.00%
Claims made from primary bank accounts on default	$ 4,100,000
Cash adjusted to various fees on default	3,900,000
Cash adjusted to principal balance of debt on default	$ 189,000
Notes payable		$ 51,700,000
Platinum Credit Facility [Member]
Liquidity [Line Items]
Notes payable		9,100,000
Remaining borrowing capacity		27,300,000
Unused additional borrowing capacity		$ 15,000,000

Fair Value (Narrative) (Details

Fair Value (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Derivative liabilities	$ 63,000		$ 63,000		$ 63,000
Recurring [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Platinum notes payable	9,500,000		9,500,000
Derivative liabilities	63,000		63,000		63,000
Transfers into Level 2	0	$ 0	0	$ 0
Transfers out of Level 2	0	0	0	0
Recurring [Member] | Quoted Prices in Active Markets for Identical Liabilities (Level 1) [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Liabilities at fair value	0	0	0	0
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Derivative liabilities	63,000		63,000		$ 63,000
Increase (decrease) in fair value of Level 3 liabilities	$ (1,500,000)	$ 1,900,000	$ (2,600,000)	$ 126,000

Fair Value (Details)

Fair Value (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Liability related to MT warrants	$ 63,000	$ 63,000
Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Platinum notes payable conversion option	416,593	3,011,880
Liability related to MT warrants	63,000	63,000
Recurring [Member] | Significant Unobservable Inputs (Level 3) [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Platinum notes payable conversion option	416,593	3,011,880
Liability related to MT warrants	$ 63,000	$ 63,000

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense including reversals of expense for forfeited or cancelled awards	$ (79,000)	$ 412,000	$ 261,000	$ 1,500,000
Number of restricted stock units vested during period			66,000
Number of unvested restricted stock units forfeited during period			206,000
Unrecognized compensation expense, Nonvested awards	$ 527,000		$ 527,000
Unrecognized compensation cost, Period for Recognition			1 year 3 months 18 days
Unvested Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of unvested restricted stock units forfeited during period			206,000
Unvested Restricted Stock [Member] | Non-Employee Directors[Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of restricted stock units vested during period			66,000
Aggregate fair value of restricted stock vested			$ 63,360

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Stock Options Activity) (Details)	6 Months Ended
	Jun. 30, 2016USD ($)$ / sharesshares
Number of Options
Outstanding at beginning of period | shares	5,437,064
Granted | shares	459,457
Canceled and Forfeited | shares	(1,504,550)
Expired | shares	(299,000)
Outstanding at end of period | shares	4,092,971
Exercisable at end of period | shares	2,808,491
Weighted Average Exercise Price
Outstanding at beginning of period, dollars per share | $ / shares	$ 1.96
Granted, dollars per share | $ / shares	1.05
Canceled and Forfeited, dollars per share | $ / shares	1.58
Expired, dollars per share | $ / shares	2.42
Outstanding at end of period, dollars per share | $ / shares	1.97
Exercisable at end of period, dollars per share | $ / shares	$ 2.05
Weighted Average Remaining Contractual Life (years)
Outstanding at end of period	7 years
Exercisable at end of period	6 years 6 months
Aggregate Intrinsic Value
Outstanding at end of period | $	$ 21,450
Exercisable at end of period | $	$ 21,450

Stock-Based Compensation (Sum33

Stock-Based Compensation (Summary of Unvested Restricted Stock) (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Number of Shares
Unvested at beginning of period, shares | shares	361,000
Granted, shares | shares	168,000
Vested, shares | shares	(66,000)
Forfeited, shares | shares	(206,000)
Unvested at end of period, shares | shares	257,000
Weighted Average Grant-Date Fair Value
Unvested at beginning of period, USD per share | $ / shares	$ 1.69
Granted, USD per share | $ / shares	1.20
Vested, USD per share | $ / shares	1.65
Forfeited,USD per share | $ / shares	1.77
Unvested at end of period, USD per share | $ / shares	$ 1.32

Earnings (Loss) Per Share (Narr

Earnings (Loss) Per Share (Narrative) (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Stock Options Warrants Convertible Debt And Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded in determining basic and diluted loss per share			14,700,000	20,300,000
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares excluded in determining basic and diluted loss per share	257,000	550,750	257,000	550,750

Inventory - Components of Inven

Inventory - Components of Inventory, Net of Reserves (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventory Disclosure [Abstract]
Materials		$ 330,000
Work-in-process	$ 65,611	392,457
Finished goods	882,115	275,168
Reserves	(177,906)	(344,719)
Total	$ 769,820	$ 652,906

Inventory (Narrative) (Details)

Inventory (Narrative) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Production Materials [Member]
Inventory [Line Items]
Inventory write-down		$ 120,000
Lymphoseek Inventory Used in Development Activity [Member]
Inventory [Line Items]
Inventory write-down	$ 36,000	$ 123,000

Investment in R-NAV, LLC (Detai

Investment in R-NAV, LLC (Details) - USD ($)	May 31, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Schedule Of Equity Method Investments [Line Items]
Payment upon termination of joint venture				$ 110,000
Loss on disposal of investment		$ (39,732)		(39,732)
Equity in loss of R-NAV, LLC		2,920	$ 6,205	15,159	$ 268,432
R-NAV [Member]
Schedule Of Equity Method Investments [Line Items]
Payment upon termination of joint venture	$ 110,000
Forgiven promissory note amount	333,333
Loss on disposal of investment		(39,732)
Equity in loss of R-NAV, LLC				15,159	268,432
Carrying value of investment	0
Commitment to provide services		$ 500,000		500,000
Cost of services provided				$ 15,000	$ 27,000
Remaining commitment to provide services	$ 383,000
R-NAV [Member] | Common Units [Member]
Schedule Of Equity Method Investments [Line Items]
Shares transferred upon termination of joint venture	3,500,000
R-NAV [Member] | Series A Preferred Units [Member]
Schedule Of Equity Method Investments [Line Items]
Shares transferred upon termination of joint venture	1,500,000

Notes Payable (Narrative) (Deta

Notes Payable (Narrative) (Details)	Jul. 01, 2016	Jun. 22, 2016USD ($)	May 31, 2016USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Aug. 01, 2016USD ($)	Jun. 28, 2016	Apr. 07, 2016	May 31, 2015USD ($)	May 15, 2015USD ($)	Jul. 31, 2012USD ($)
Debt Instrument [Line Items]
Compounded interest on notes payable				$ 352,000	$ 429,000	$ 1,176,931	$ 429,074
Notes payable				61,200,000		61,200,000
Change in fair value of financial instruments				1,469,928	(1,852,730)	2,595,287	(125,627)
Lymphoseek sales revenue				4,231,719	1,963,548	8,014,399	3,798,970	$ 10,300,000
Net interest expense				7,500,000	1,600,000	9,700,000	2,500,000
Interest expense recorded related to amortization				5,000	146,000	$ 77,964	358,924
R-NAV [Member]
Debt Instrument [Line Items]
Joint venture, effective date of termination						May 31, 2016
Remaining amount on promissory note forgiven			$ 333,333
Cardinal Health [Member]
Debt Instrument [Line Items]
Percentage of receivables due from customers										50.00%
Remaining percentage of receivables due from customers held in escrow account										50.00%
Subsequent Event [Member] | Cardinal Health [Member]
Debt Instrument [Line Items]
Percentage of receivables due from customers									75.00%
Remaining percentage of receivables due from customers held in escrow account									25.00%
Percentage of receivables due from customers after reaching escrow account limit									100.00%
Subsequent Event [Member] | Cardinal Health [Member] | Maximum [Member]
Debt Instrument [Line Items]
Escrow account threshold target amount									$ 1,000,000
Platinum Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity, amount														$ 50,000,000
Current borrowing capacity														$ 35,000,000
Compounded interest on notes payable						$ 624,000
Debt instrument effective rate						In accordance with the terms of the Section 16(b) Settlement Agreement discussed in Note 15(c), Platinum agreed to forgive interest owed on the credit facility in an amount equal to 6%, effective July 1, 2016.
Notes payable				9,100,000		$ 9,100,000
Remaining borrowing capacity				27,300,000		27,300,000
Unused additional borrowing capacity				15,000,000		15,000,000
Platinum notes payable				417,000		417,000
Change in fair value of financial instruments				(1,500,000)	$ 1,900,000	(2,600,000)	$ 126,000
Estimated fair value				9,500,000		9,500,000
Platinum Credit Facility [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Percentage of interest forgiven on credit facility	6.00%
Capital Royalty Partners II LP [Member]
Debt Instrument [Line Items]
Compounded interest on notes payable						553,000
Notes payable				51,700,000		$ 51,700,000
Debt instrument face amount												$ 50,000,000
Debt instrument, unused borrowing capacity												$ 10,000,000
Payment terms						2 years
Debt discount related to lender fees and other costs													$ 2,200,000
End-of-term fee amount				1,000,000		$ 1,000,000							1,000,000
Minimum amount of yearly EBITDA required under agreement						5,000,000
Minimum sales revenue target						$ 22,500,000		11,000,000
Minimum sales revenue target in 2020													45,000,000
Cure right ratio						2.5
Liquidity minimum				$ 5,000,000		$ 5,000,000							$ 5,000,000
Debt instrument default interest rate percentage				18.00%		18.00%					18.00%
Reduced minimum sales revenue target in 2015								$ 10,000,000
Obligations under loan agreement due and payable			$ 56,157,240.69
Claims made from primary bank accounts on default		$ 4,100,000
Cash adjusted to collection of collateral, on claims of default		778,000				$ 778,000
Cash adjusted to prepayment premium, on claims of default		2,100,000				2,100,000
Cash adjusted to backend facility fee, on claims of default		1,000,000
Cash adjusted to principal balance of debt on default		$ 189,000
Notes payable, discounts				$ 2,000,000		2,000,000
Capital Royalty Partners II LP [Member] | Accrued Liabilities and Other [Member]
Debt Instrument [Line Items]
Accrued interest				$ 2,300,000		$ 2,300,000

Commitments and Contingencies (

Commitments and Contingencies (Narrative) (Details) - USD ($)	Jun. 22, 2016	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015	Aug. 01, 2016	Jun. 28, 2016	May 31, 2016	Apr. 07, 2016
Loss Contingencies [Line Items]
Lymphoseek sales revenue		$ 4,231,719	$ 1,963,548	$ 8,014,399	$ 3,798,970	$ 10,300,000
Cardinal Health [Member]
Loss Contingencies [Line Items]
Percentage of receivables due from customers								50.00%
Remaining percentage of receivables due from customers held in escrow account								50.00%
Cardinal Health [Member] | Subsequent Event [Member]
Loss Contingencies [Line Items]
Percentage of receivables due from customers							75.00%
Remaining percentage of receivables due from customers held in escrow account							25.00%
Percentage of receivables due from customers after reaching escrow account limit							100.00%
Cardinal Health [Member] | Subsequent Event [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Escrow account threshold target amount							$ 1,000,000
Capital Royalty Partners II LP [Member]
Loss Contingencies [Line Items]
Debt instrument default interest rate percentage		18.00%		18.00%						18.00%
Minimum sales revenue target				$ 22,500,000		11,000,000
Reduced minimum sales revenue target in 2015						$ 10,000,000
Obligations under loan agreement due and payable									$ 56,157,240.69
Claims made from primary bank accounts on default	$ 4,100,000
Cash adjusted to collection of collateral, on claims of default	778,000			778,000
Cash adjusted to prepayment premium, on claims of default	2,100,000			$ 2,100,000
Cash adjusted to backend facility fee, on claims of default	1,000,000
Cash adjusted to principal balance of debt on default	$ 189,000

Equity Instruments (Narrative)

Equity Instruments (Narrative) (Details)	6 Months Ended
	Jun. 30, 2016USD ($)shares
Class Of Stock [Line Items]
Common stock issued in lieu of cash compensation	$ 34,820
Common Stock [Member]
Class Of Stock [Line Items]
Common stock issued in lieu of cash compensation | shares	29,069
Common stock issued in lieu of cash compensation	$ 29
Board of Directors [Member] | Common Stock [Member]
Class Of Stock [Line Items]
Common stock issued in lieu of cash compensation | shares	29,069
Common stock issued in lieu of cash compensation	$ 34,820

Stock Warrants (Narrative) (Det

Stock Warrants (Narrative) (Details)	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Class of Warrant or Right [Line Items]
Warrants outstanding (shares) | shares	11,700,000
Common Stock [Member] | Macrophage Therapeutics [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 2,000
Outstanding number of warrant to be converted to common stock | shares	300
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 0.01
Warrant, Outstanding Term	1 year
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 3.04
Warrant, Outstanding Term	19 years
Weighted Average [Member]
Class of Warrant or Right [Line Items]
Exercise price of warrant issued, dollars per share	$ 0.38

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Liability for uncertain tax positions	$ 0	$ 0

Segments (Narrative) (Details)

Segments (Narrative) (Details)	6 Months Ended
	Jun. 30, 2016Segment
Segment Reporting [Abstract]
Number of reporting segments	2

Segments (Details)

Segments (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2015
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	$ 4,231,719	$ 1,963,548	$ 8,014,399	$ 3,798,970	$ 10,300,000
Lymphoseek license revenue	245,950	250,000	500,000	333,333
Grant and other revenue	916,811	654,360	1,602,636	844,061
Total revenue	5,394,480	2,867,908	10,117,035	4,976,364
Cost of goods sold, excluding depreciation and amortization	546,466	304,495	1,041,105	725,046
Research and development expenses, excluding depreciation and amortization	2,525,581	2,292,524	5,185,101	6,269,262
Selling, general and administrative expenses, excluding depreciation and amortization	2,784,637	3,932,267	6,771,995	9,309,669
Depreciation and amortization	117,778	149,317	267,370	299,139
Income (loss) from operations	(579,982)	(3,810,695)	(3,148,536)	(11,626,752)
Other income (expense), excluding equity in the loss of R-NAV, LLC	(6,098,405)	(5,874,019)	(7,203,861)	(5,086,960)
Equity in the loss of R-NAV, LLC	(2,920)	(6,205)	(15,159)	(268,432)
Net income (loss)	(6,681,307)	(9,690,919)	(10,367,556)	(16,982,144)
Total assets, net of depreciation and amortization	8,682,149		8,682,149		$ 14,964,513
Payments to Acquire Property, Plant, and Equipment	1,847	27,618	1,847	27,618
United States [Member]
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	4,218,606	1,962,898	7,990,026	3,793,920
Total assets, net of depreciation and amortization	8,360,199	21,726,705	8,360,199	21,726,705
International [Member]
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	13,113	650	24,373	5,050
Total assets, net of depreciation and amortization	321,950	471,884	321,950	471,884
Corporate [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative expenses, excluding depreciation and amortization	1,644,649	2,339,207	4,620,499	5,660,068
Depreciation and amortization	103,504	116,532	212,806	233,298
Income (loss) from operations	(1,748,153)	(2,455,739)	(4,833,305)	(5,893,366)
Other income (expense), excluding equity in the loss of R-NAV, LLC	(6,098,405)	(5,874,019)	(7,203,861)	(5,086,960)
Equity in the loss of R-NAV, LLC	(2,920)	(6,205)	(15,159)	(268,432)
Net income (loss)	(7,849,478)	(8,335,963)	(12,052,325)	(11,248,758)
Payments to Acquire Property, Plant, and Equipment	1,847	2,126	1,847	2,126
Corporate [Member] | United States [Member]
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	3,701,620	17,690,779	3,701,620	17,690,779
Corporate [Member] | International [Member]
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	591	1,851	591	1,851
Diagnostics [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Lymphoseek license revenue	245,950	250,000	500,000	333,333
Grant and other revenue	865,359	654,360	1,551,184	844,061
Total revenue	5,343,028	2,867,908	10,065,583	4,976,364
Cost of goods sold, excluding depreciation and amortization	546,466	304,495	1,041,105	725,046
Research and development expenses, excluding depreciation and amortization	2,414,255	2,115,786	4,831,975	6,006,510
Selling, general and administrative expenses, excluding depreciation and amortization	1,135,558	1,529,042	2,147,664	3,571,217
Depreciation and amortization	14,274	32,785	54,564	65,841
Income (loss) from operations	1,232,475	(1,114,200)	1,990,275	(5,392,250)
Net income (loss)	1,232,475	(1,114,200)	1,990,275	(5,392,250)
Payments to Acquire Property, Plant, and Equipment		25,492		25,492
Diagnostics [Member] | Operating Segments [Member] | United States [Member]
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	4,218,606	1,962,898	7,990,026	3,793,920
Total assets, net of depreciation and amortization	4,621,738	4,035,926	4,621,738	4,035,926
Diagnostics [Member] | Operating Segments [Member] | International [Member]
Segment Reporting Information [Line Items]
Lymphoseek sales revenue	13,113	650	24,373	5,050
Total assets, net of depreciation and amortization	321,359	470,033	321,359	470,033
Therapeutics [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Grant and other revenue	51,452		51,452
Total revenue	51,452		51,452
Research and development expenses, excluding depreciation and amortization	111,326	176,738	353,126	262,752
Selling, general and administrative expenses, excluding depreciation and amortization	4,430	64,018	3,832	78,384
Income (loss) from operations	(64,304)	(240,756)	(305,506)	(341,136)
Net income (loss)	(64,304)	$ (240,756)	(305,506)	$ (341,136)
Therapeutics [Member] | Operating Segments [Member] | United States [Member]
Segment Reporting Information [Line Items]
Total assets, net of depreciation and amortization	$ 36,841		$ 36,841

Segments (Parenthetical) (Detai

Segments (Parenthetical) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 117,778	$ 149,317	$ 267,370	$ 299,139
Cost of Goods Sold [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	14,274	28,235	54,564	56,741
Research and Development [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	0	4,550	0	9,100
Selling, General and Administrative Expenses [Member]
Segment Reporting Information [Line Items]
Depreciation and amortization	$ 103,504	$ 116,532	$ 212,806	$ 233,298

Supplemental Disclosure for S46

Supplemental Disclosure for Statements of Cash Flows (Details) - USD ($)	Jun. 22, 2016	Jun. 30, 2016	Jun. 30, 2015
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Cash paid during the period for interest		$ 4,200,000	$ 2,000,000
Issued stock to 401(k) plan, shares			68,157
Issued stock to 401(k) plan for employer matching contributions		0	$ 117,099
Capital Royalty Partners II LP [Member]
Supplemental Disclosure For Statements Of Cash Flows [Line Items]
Collection fees included in interest paid	$ 778,000	778,000
Prepayment premium included in interest paid	$ 2,100,000	$ 2,100,000
Notes payable end of term fees			$ 1,000,000

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details) - USD ($)	Jul. 31, 2016	Jul. 01, 2016	May 31, 2016	Dec. 31, 2015	Aug. 01, 2016	Jun. 30, 2016	Jun. 28, 2016
Subsequent Event [Line Items]
Current liability in form of compensation				$ 6,183,850		$ 62,392,372
Macrophage Therapeutics [Member]
Subsequent Event [Line Items]
Additional investment contribution amount			$ 200,000	200,000
Current liability in form of compensation						$ 200,000
Authorized issuance of additional convertible preferred stock			$ 200,000	$ 200,000
Cardinal Health [Member]
Subsequent Event [Line Items]
Percentage of receivables due from customers							50.00%
Remaining percentage of receivables due from customers held in escrow account							50.00%
Subsequent Event [Member] | Macrophage Therapeutics [Member]
Subsequent Event [Line Items]
Percentage of paid-in-kind coupon rate on convertible preferred stock	10.00%
Initial market capitalization	$ 500,000,000
Subsequent Event [Member] | Macrophage Therapeutics [Member] | Dr. Goldberg [Member]
Subsequent Event [Line Items]
Authorized modification of original investments	200,000
Subsequent Event [Member] | Platinum Credit Facility [Member]
Subsequent Event [Line Items]
Percentage of interest forgiven on credit facility		6.00%
Subsequent Event [Member] | Platinum Credit Facility [Member] | Macrophage Therapeutics [Member]
Subsequent Event [Line Items]
Authorized modification of original investments	$ 300,000
Subsequent Event [Member] | Cardinal Health [Member]
Subsequent Event [Line Items]
Percentage of receivables due from customers					75.00%
Remaining percentage of receivables due from customers held in escrow account					25.00%
Percentage of receivables due from customers after reaching escrow account limit					100.00%
Subsequent Event [Member] | Maximum [Member] | Cardinal Health [Member]
Subsequent Event [Line Items]
Escrow account threshold target amount					$ 1,000,000